TYF-IL-2Rg gene-modified autologous stem cells (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTYF-IL-2Rg gene-modified autologous stem cells (Shenzhen Geno-Immune Medical Institute)
Drug Alias NameStem cell gene therapy (X-linked severe combined immunodeficiency)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionInterleukin-2 receptor subunit gamma stimulants
TargetsInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsX-Linked Combined Immunodeficiency Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsX-Linked Combined Immunodeficiency Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A